{"href":"http://player.captivate.fm/services/oembed?url=http%3A%2F%2Fplayer.captivate.fm%2Fepisode%2F9d927c78-ea5b-465c-822f-e0ff85f68359","version":"1.0","provider_name":"Captivate.FM","provider_url":"https://www.captivate.fm","width":600,"height":200,"type":"rich","html":"<iframe style=\"width: 100%; height: 200px;\" title=\"Integrating Antibody-Drug Conjugates into the Management of HR-Positive and Triple-Negative Metastatic Breast Cancer\" frameborder=\"0\" scrolling=\"no\" allow=\"clipboard-write\" seamless src=\"http://player.captivate.fm/episode/9d927c78-ea5b-465c-822f-e0ff85f68359\"></iframe>","title":"Integrating Antibody-Drug Conjugates into the Management of HR-Positive and Triple-Negative Metastatic Breast Cancer","description":"\n        <p>Dr Sara A Hurvitz from the Fred Hutchinson Cancer Center in Seattle, Washington, summarizes recent trials investigating the integration of antibody-drug conjugates for HR-positive and triple-negative metastatic breast cancer, moderated by Dr Neil Love. Produced by Research To Practice. </p>\n\n<p>CME information and select publications <a href=\"https://www.researchtopractice.com/OncologyTodayADCsmBC24\" rel=\"nofollow\">here</a>. </p>\n      ","thumbnail_width":300,"thumbnail_height":300,"thumbnail_url":"https://artwork.captivate.fm/ff2c3382-ea2c-47b2-a8be-9c4abd8f55a3/cover.jpg"}